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Objectives. We studied the duration and prognostic significance 
of atrial arrhythmias in the denervated transplanted heart, spe- 
cifically the occurrence ofatrial fibrillation in the absence of vagal 
modulation. 
Background. Substantial animal data indicate that vagally 
induced ispersion of atrial refractoriness plays a central role in 
the induction and maintenance ofatrial fibrillation. 
Methods. We studied the occurrence of atrial arrhythmias in 
the denervated hearts of 88 consecutive orthotopic transplanta- 
tions in 85 patients by means of continuous telemetry and all 
available lectrocardiographic tracings. 
Results. Fifty percent of recipients (44 of 88) developed at least 
one atrial arrhythmia. Atrial fibrillation occurred 23 times (21 
recipients), atrial flutter 39 times (26 recipients), ectopic atrial 
tachycardia 3 times (3 recipients) and supraventricular t chycar- 
dia 18 times (11 recipients). The number of atrial fibrillation and 
atrial flutter episodes did not differ (23 vs. 39, p = 0.072), but the 
mean duration of atrial flutter was longer than that of atrial 
fibrillation (37.0 + 10 vs. 6.6 -+ 3.6 h, p = 0.014). Atrial fibrillation 
was associated with an increased risk of subsequent death (10 of 
21 recipients with vs. 15 of 67 without atrial fibrillation, risk ratio 
3.15 -+ 0.18, p = 0.005 by Cox proportional hazards model). All 5 
recipients who developed "late" atrial fibrillation (>2 weeks after 
transplantation) died versus 5 of 16 who developed atrial fibril- 
lation within the first 2 weeks (p = 0.007). Causes of death 
included rejection (three recipients), allograft failure (two recip- 
ients), infection (three recipients) and multiorgan failure (two 
recipients). Atrial fibrillation was not associated with age, gender, 
ischemic time, reason for transplantation, echocardiographic 
variables, invasive hemodynamic variables or biopsy grade. Mean 
time from atrial arrhythmia to echocardiography was 2.7 -+ 3.3 
days; that to biopsy was 4.8 -+ 6.3 days. Atrial flutter was not 
associated with subsequent death. Only 7 (15.9%) of 44 recipients 
demonstrated moderate or severe allograft rejection at the time of 
the arrhythmia. 
Conclusions. Atrial arrhythmias occur frequently in the dener- 
vated transplanted heart, often in the absence of significant 
rejection. Late atrial fibrillation may be associated with an 
increased all-cause mortality. 
(J Am Coll Cardio11995;25:1673- 80) 
Substantial clinical and experimental evidence suggests that 
vagal tone and acetylcholine play a crucial role in the genesis of 
atrial fibrillation (1-9). This profibrillatory influence may be 
due to the inhomogeneous effects of vagal stimulation on 
different parts of the atria (10), the effects being more pro- 
nounced in the right than in the left atrium in the canine model 
(11). Vagal tone shortens the atrial refractory period, and this 
effect, distributed unequally over the two atria, may also 
contribute to ease of induction of atrial fibrillation. Vagal 
modulation thus increases the inhomogeneity or dispersion of 
atrial refractoriness, resulting in nonuniform wavefront prop- 
agation, and thereby facilitates atrial fibrillation (6). 
In humans, atrial fibrillation has been induced by direct 
injection of acetylcholine into the carotid artery (12) and by 
simple carotid sinus massage (13). Whether atrial fibrillation 
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can be sustained in a normal heart in the absence of vagal tone 
is unclear, although some investigators (14) have documented 
atrial fibrillation after transplantation and concluded that 
autonomic innervation of the heart is not a prerequisite for the 
development of cardiac arrhythmias. Orthotopic ardiac trans- 
plantation affords a unique model for studying the behavior of 
denervated human atria. Published studies (14-19) have sug- 
gested that the occurrence of atrial arrhythmias may be a 
marker of underlying allograft rejection. Thus, in the clinical 
setting the new onset of an atrial arrhythmia frequently 
prompts endomyocardial biopsy and two-dimensional echocar- 
diography. However, other studies (20-22) have found that 
arrhythmias can occur in the absence of histologically docu- 
mented rejection. The aim of this study was to examine the 
prevalence, duration and prognostic significance of atrial ar- 
rhythmias after orthotopic ardiac transplantation. 
Methods  
Patients. We retr0~pectively reviewed the medical records 
of 88 consecutive orthotopic cardiac transplantations per- 
formed in 85 patients at our institution between November 
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1985 and January 1994. Indications for cardiac transplantation 
included heart failure due to ischemic heart disease (49%), 
dilated cardiomyopathy (37%), valvular heart disease (7%), 
congenital heart disease (6%) and hypertrophic cardiomyopa- 
thy (1%). Hemodynamic monitoring with pulmonary artery 
catheters was discontinued within the first 2 to 8 days after 
transplantation. Electrolytes and acid-base status were closely 
followed and any abnormalities aggressively treated. Atrial and 
ventricular pacing wires were removed as soon as pacing was 
not required for hemodynamic stability. All patients received 
triple-drug immunosuppressive th rapy with prednisone, aza- 
thioprine and cyclosporine. Routine surveillance right ventric- 
ular endomyocardial biopsy was performed weekly for the first 
postoperative month, biweekly for the next 8 weeks and 
monthly for the remainder of the first year. Biopsies were also 
performed for any change in clinical status judged to be 
indicative of allograft rejection. Moderate (International Soci- 
ety of Heart and Lung Transplantation [23] grade 2 or 3A) 
cellular rejection ot associated with hemodynamic compro- 
mise was treated with methyl prednisolone (24). Additional 
cytolytic therapy (antithymocyte globulin or OKT3) was used 
for hemodynamically significant allograft rejection of any 
histologic severity. 
Arrhythmia analysis. All patients underwent continuous 
electrocardiographic (ECG) telemetric monitoring for the 
entire duration of their initial hospital stay and during all 
subsequent hospital readmissions. Routine 12-1ead ECGs were 
recorded daily for all patients during the first week after 
transplantation and before hospital discharge. All available 
ECG tracings (including telemetry strips, surface ECGs, intra- 
cardiac electrograms recorded from temporary atrial pacing 
wires and Holter recordings) were reviewed to establish the 
presence or absence, and mechanism of, any atrial arrhythmia. 
All physician notes and nursing flow sheets were studied to 
accurately determine the timing and duration of each atrial 
event. 
Atrial arrhythmias that developed within the first 2 weeks 
after transplantation were defined as early atrial arrhythmias; 
those that developed after the first 2 weeks were defined as late 
atrial arrhythmias. Atrialfibrillation was diagnosed when there 
was either no discernible or completely unorganized atrial 
activity, associated with an irregularly irregular ventricular 
response. Atrial flutter was diagnosed when there was dearly 
discernible atrial activity at a fixed atrial cycle length between 
the rates of 250 and 350 beats/min. Ectopic atrial tachycardia 
was defined as a rhythm, regular or irregular, where a p wave 
with an axis and configuration different from normal sinus 
rhythm preceded each QRS complex. Supraventricular tachy- 
cardia was defined as a regular, narrow complex arrhythmia 
without obvious p waves, that could not be categorized in to 
any of the previous groups. 
Time to atrial arrhythmia fter transplantation and dura- 
tion of each episode were recorded. Invasive hemodynamic, 
two-dimensional echocardiographic and biopsy findings data 
were recorded for each patient from studies performed closest 
to the time of the atrial arrhythmia. These data were then 
compared with those obtained from the group of patients 
without any atrial arrhythmia (control transplant recipients) at 
matched times after transplantation. All variables (age, gen- 
der, length of index hospital stay, ischemic time, echocardio- 
graphically measured atrial dimensions, semiquantitative d - 
gree of tricuspid regurgitation, right ventricular function score, 
left ventricular ejection fraction, rest filling pressure and 
cardiac output measured at right heart catheterization, histo- 
logic grade of rejection) that could potentially influence the 
occurrence of atrial arrhythmias were recorded. Tricuspid 
regurgitation was scored as follows: trace = 1; mild = 2; 
moderate = 3; severe = 4. For statistical comparison, right 
ventricular function was scored as follows: normal = 1; mild 
hypokinesia = 2; moderate hypokinesia = 3; severe hypokinesia = 4. 
Statistical analysis. Statistical analysis was performed with 
Kaplan-Meier survival analysis to assess the univariate impact 
of atrial fibrillation on mortality; stepwise multiple logistic 
regression to seek determinants of atrial fibrillation, atrial 
flutter, ectopic atrial tachycardia nd supraventricular tachy- 
cardia; and stepwise Cox hazards regression models to test 
potential multivariate predictors of mortality. The BMDP 
Statistical Software package, release 7, (Dixon, WJ, editor. 
Berkeley [CA]: University of California Press) was used for 
these calculations. A p value < 0.05 was considered statistically 
significant. Results are expressed as the mathematical mean _+ 
SE. If the first allograft did not survive and the patient required 
retransplantation, then the failure of the first heart was 
counted as a "death," even if the patient survived after 
receiving the second allograft. For the purpose of statistical 
analysis and simplicity in discussion, the three patients who 
underwent retransplantation, were counted as six "recipients"; 
the total number of recipients in this study was therefore 88. 
Results 
The clinical characteristics and ischemic times for the entire 
transplantation cohort, as well as for those patients who 
developed an atrial arrhythmia, and are shown in Table 1. 
Atrial arrhythmias. A total of 44 (50%) of the 88 recipi- 
ents had at least one episode of atrial arrhythmia. Atrial 
fibrillation occurred 23 times in 21 recipients (24% of the total 
number of recipients), atrial flutter 39 times in 26 recipients 
(30%), ectopic atrial tachycardia 3 times in 3 recipients (3%) 
and supraventricular tachycardia 18 times in 11 recipients 
(13%). Nine patients had episodes of both atrial flutter and 
atrial fibrillation, two of whom also had episodes of supraven- 
tricular tachycardia (Fig. 1). The number of episodes of atrial 
flutter (39) was greater than that for atrial fibrillation (23), but 
the difference was not statistically significant (p = 0.072). The 
shortest duration of atrial fibrillation recorded in the present 
study was 3 rain, and that for atrial flutter was 90 rain. Mean 
duration of atrial flutter was 37 _+ 10 h (range 90 rain to 9 
days), significantly greater than that for atrial fibrillation (6.6 _+ 
3.6 h, range 3 rain to 3 days, p = 0.014 for comparison of 
arrhythmia duration). Four episodes of atrial flutter were 
either pace terminated or electrically cardioverted to normal 
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Table 1. Clinical Characteristics of the Study Group by Atrial Arrhythmia Type 
Recipients Without 
Atrial Arrhythmias 
Recipients With Recipients With Recipients With Recipients With (control transplant 
Entire Group Atrial Fibrillation Atrial Flutter EAT SVT recipients) 
(n = 88) (n = 21) (n = 26) (n = 3) (n = 11) (n = 44) 
Age 52 -+ 10 50 _+ 2 53 + 2 51 _+ 4 57 _+ 2 52 _+ 2 
Gender 
Male 74 (87%) 18 (86%) 23 (89%) 2 (67%) 8 (73%) 40 (91%) 
Female 11 (13%) 3 (14%) 3 (11%) 1 (33%) 3 (27%) 4 (9%) 
Reason for transplantation 
CAD 42 (49%) 5 (24%) 11 (42%) 1 (33%) 6 (55%) 25 (57%) 
DCM 31 (37%) 10 (48%) 10 (38%) 2 (67%) 2 (18%) 14 (32%) 
Congenital disease 5 (6%) 4 (19%) 3 (12%) 0 2 (18%) 2 (4%) 
Valvular disease 6 (7%) 2 (9%) 1 (4%) 0 1 (9%) 3 (7%) 
HCM 1 (1%) 0 1 (4%) 0 0 0 
Ischemic time (min) 162 + 5 170 _+ 14 162 _+ 5 149 _+ 7 168 _+ 9 160 _+ 7 
Data presented are mean value _+SEM or number (%) of patients. CAD = coronary artery disease; DCM (HCM) = dilated (hypertrophic) cardiomyopathy; EAT = 
ectopic atrial tachycardia; SVT = supraventricular tachycardia. 
sinus rhythm. Table 2 summarizes the characteristics of each 
type of atrial arrhythmia. 
Early atrial fibrillation occurred in 16 (76%) of 21 recipients 
(mean time of onset 5.9 + 1.3 days, range 0 to 14); the 
remaining 5 recipients (24%) had late atrial fibrillation (mean 
time of onset 322 _ 224 days, range 31 to 1213). Nineteen of 
26 recipients (73%) had early atrial flutter (mean time of onset 
4.1 _ 0.7 days, range 0 to 13); the remaining seven recipients 
had late atrial flutter (mean time of onset 84.6 ___ 28.4 days, 
range 20 to 180). Two of the 3 recipients with ectopic atrial 
tachycardia nd 8 of the 11 recipients with supraventricular 
tachycardia had the arrhythmia during the first 2 weeks. 
Overall, early atrial arrhythmias were recognized in 30 (34%) 
of 88 recipients, late arrhythmias in 10 (11%) of 88 and both 
early and late arrhythmias in 4 (5%) of 88. 
Determinants of arrhythmia. Stepwise multiple logistic 
regression demonstrated that the occurrence of atrial fibrilla- 
tion was not associated with age; gender; length of index 
hospital period; donor ischemic time; two-dimensional echo- 
cardiographic variables including left atrial size, right ventric- 
ular function score, semiquantitative d gree of tricuspid regur- 
Figure 1. Venn diagrammatic representation f numbers of patients 
(not recipients) with atrial arrhythmias. EAT = ectopic atrial tachy- 
cardia; FIB = atrial fibrillation, FLU = atrial flutter; SVT = supraven- 
tricular tachycardia. 
FIB FLU 
( 2 1 ) ~  
(3) 
gitation and left ventricular ejection fraction; right heart 
hemodynamic variables, including right atrial pressure, pulmo- 
nary artery pressure, pulmonary capillary wedge pressure and 
cardiac output; or the grade of rejection on endomyocardial 
biopsy (all p = NS) (Table 3). Mean time from onset of atrial 
arrhythmia to echocardiography was 2.7 __ 3.3 days (range 0 to 
12.5) and that for endomyocardial biopsy was 4.8 _+ 6.3 days 
(range 0 to 33.5). Only 7 (16%) of 44 recipients had a biopsy 
grade ->2 (i.e., at least moderate) rejection at the time of the 
arrhythmia. One patient demonstrated severe (grade 3B) 
rejection. Four (9%) of the 44 recipients without any atrial 
arrhythmias (i.e., control transplant recipients) had moderate 
rejection at matched times after transplantation (p = 0.41 for 
comparison of number of biopsies that showed moderate 
rejection in patients with and without any atrial arrhythmia). 
Episodes of atrial flutter, ectopic atrial tachycardia nd su- 
pmventricular tachycardia were also not associated with any of 
the clinical, echocardiographic, hemodynamic or histologic 
variables examined. 
Deaths. Actuarial survival for all transplant recipients was 
79%, 73% and 57% at 1, 3 and 5 years, respectively. There 
were a total of 25 deaths during follow-up, which averaged 
777 -+ 71 days. 
Atrial fibrillation and death. Atrial fibrillation was docu- 
mented in 10 (40%) of the 25 recipients who subsequently died 
during this study. The occurrence of atrial fibrillation was 
associated with an increased risk of death (10 [48%] of 21 
recipients with recognized atrial fibrillation did not survive vs. 
15 [22%] of 67 without atrial fibrillation; risk ratio 3.15 _+ 0.18, 
p = 0.005 by Cox proportional hazards modeling). The risk 
ratio for death in recipients with versus without recognized 
atrial fibrillation was 3.5 _+ 0.18. Figure 2 shows the Kaplan- 
Meier survival plots for recipients with and without recognized 
atrial fibrillation. All 5 recipients (100%) with recognized late 
atrial fibrillation died compared with 5 (31%) of 16 recipients 
who developed early atrial fibrillation (p = 0.007). Mean time 
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Table 2. Characteristics of Observed Atrial Arrhythmias 
No. of No. of 
Recipients Episodes 
Mean (_+SEM) 
Mean (_+SEM) Time From Transplantation 
Duration of Each Episode to First Episode 
(rain) (days) 
Atrial fibrillation 21 23 
Atrial flutter 26 39 
EAT 3 3 
SVT 11 18 
393 + 215 81 -+ 57 
2,219 -+ 600 26 + 10 
<1 8+6 
3+1 88_+78 
Abbreviations a in Table 1. 
from occurrence of the first atrial fibrillation episode to death 
was 77 _+ 57 days, and that for atrial flutter to death was 271 __ 
230 days (p = 0.40). 
Causes of death. Twelve of the 25 recipients who died 
during this study had a previous episode of atrial arrhythrnia. 
Of these 12 patients, 5 died of cardiac-related causes, 5 of 
infectious complications and 2 of multiorgan failure. Rejec- 
tion-related mortality did not appear to be increased in the 
atrial fibrillation group (three recipients had biopsy-proved 
moderate rejection in the atrial fibrillation group vs. one 
Table 3. Clinical, Echocardiographic, Hemodynamie and Histologic 
Variables in Recipients With and Without Atrial Fibrillation 
Recipients With Recipients Without 
Atrial Atrial 
Fibrillation Fibrillation p 
Variable (n = 21) (n = 67) Value 
Clinical 
Age (yr) 47 _+ 2.5 51 +_ 1.3 0.20 
Gender (M/F) 18/3 58/9 0.92 
Ischemic time (min) 170 -+ 4.9 160 _+ 13.7 0.43 
Hospital stay (days) 23.6 24.4 0.39 
Echocardiographic 
LA size (mm) 47.2 _+ 2.6 46.3 _+ 1.31 0.32 
Amount of TR 2.6 -+ 0.25 2.3 _+ 0.12 0.23 
RV Size 2.1 +_ 0.2 1.6 + 0.11 0.06 
RV Function 1.8 -+ 0.24 1.5 -+ 0.01 0.17 
LV EF 58.2 -+ 3.6 62.6 _+ 1.34 0.16 
Hemodynamic 
RA pressure (mm HzO) 8.1 _+ 1.06 8.2 + 0.67 0.91 
PA pressure (mm Hg) 35.3 _+ 1.6 34.5 _+ 1.0 0.68 
PCW pressure (mm Hg) 11.5 --- 1.11 12.5 _+ 0.66 0.48 
Cardiac output (liters/rain) 5.6 + 0.65 4.9 _+ 0.18 0.17 
Histologic findings 
Grade 0 12 (57.1%) 47 (70.1%) NS 
Grade 1A or 1B 5 (23.8%) 14 (20.9%) NS 
Grade 2 or 3 4 (19.1%) 6 (9.0%) 0.19 
Data presented are mean value _+ SEM or number (%) of recipients. EF = 
ejection fraction; F = female; Histologic findings = International Society for 
Heart and Lung Transplantation grading system (0, 1A, 1B, 2, 3A, 3B, 4); LA 
(RA) = left (right) atrial; LV = left ventricular; M = male; PA = pulmonary 
artery; PCW =" pulmonary capillary wedge; RV function = right ventricular 
function (1 - normal, 2 = mild hypokinesia, 2 = moderate hypokinesia, 3 = 
moderate hypokinesia, 4 = severe hypokinesia); RV size = right ventricular size 
(1 = normal, 2= mild dilation, 3= moderate dilation, 4 = severe dilation); TR 
severity = tricuspid regurgitation severity (1 = trace, 2 = mild, 3 = moderate, 
4 = severe). 
recipient in the atrial flutter group, p = NS) (Table 4). Of 13 
patients without any documented atrial arrhythmia, 7 died of 
cardiac-related and 6 of non-cardiac-related causes. 
Atrial flutter, eetopic atrial tachycardia, supraventricular 
tachycardia and death. Atrial flutter was not associated with an 
increased likelihood of death (9 [35%] of 26 patients with atrial 
with and 16 [26%] of 62 without atrial flutter died, p = 0.41). 
Further, seven of nine patients in the atrial flutter group who 
subsequently died also had an episode of atrial fibrillation. 
Ectopic atrial tachycardia (no deaths) and supraventricular 
tachycardia (2 [18%] of 11 patients with supraventricular vs. 23 
[30%] of 77 without tachycardia died, p = 0.42) were also not 
associated with an increased risk of death. 
Other variables and death. Death was not associated with 
duration of atrial fibrillation, reason for transplantation, echo- 
cardiographic variables measured at the time of the arrhythmia 
(left atrial size, right ventricular size, right ventricular function 
score, amount of tricuspid regurgitation), hemodynamic vari- 
ables measured at the time of the arrhythmia (right atrial 
pressure, pulmonary artery pressure, pulmonary capillary 
wedge pressure), or biopsy grade (all p = NS). Death was 
significantly associated with a decreased left ventricular ejec- 
tion fraction measured at the time of the arrhythmia (0.55 +_ 
Figure 2. Kaplan-Meier survival curves in patients with (dashed line) 
and without (solid line) atrial fibrillation. 
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Table 4. Cause of Death by Atrial Arrhythmia 
Atrial Fibrillation Atrial Flutter 
(10 deaths) (9 deaths) 
Supraventricular No Atrial 
Tachycardia Arrhythmia 
(2 deaths) (13 deaths) 
Cardiac etiology 
Noncardiac etiology 
Graft dysfunction Graft dysfunction* 
Rejection (3recipients) Rejection* 
RV failure RV failure* 
Fungal pneumonia Fungal pneumonia* 
Sepsis (2 recipients) Sepsis* 
Multiorgan failure Multiorgan f ilure* 
Hepatic failure Hepatic failure* 
Pneumonia 
Pulmonary failure 
Graft dysfunction* Graft dysfunction 
Rejection 




Hepatic failure* Hepatic failure 
Pancreatitis 
Lymphoma (3 recipients) 
ARDS 
*Patients who also had atrial fibrillation. ARDS = adult respiratory distress yndrome; RV = right ventricular. 
0.03 in patients who subsequently died vs. 0.64 _+ 0.01 in 
survivors, p = 0.03 by Cox proportional hazards model). 
Duration of atrial fibrillation was not significantly associ- 
ated with the likelihood of subsequent death. Seven of 21 
patients had atrial fibrillation that lasted <7 rain. However, 
four of these seven patients died, and mean time from first 
occurrence of atrial fibrillation to death in these four patients 
was 35.2 + 13.4 days (range 7 to 71). In the remaining six 
patients with atrial fibrillation who subsequently died, mean 
time to death from first episode of atrial fibrillation was 
105.0 + 97.2 days (range 1 to 591, p = 0.58 for mean time to 
death). Mean left ventricular ejection fraction was 0.62 _+ 0.03 
in the four patients with brief atrial fibrillation who subse- 
quently died compared with 0.44 +_ 0.07 in the six patients with 
more sustained atrial fibrillation who subsequently died; how- 
ever, this difference did not reach statistical significance (p = 
0.08). 
Discussion 
Animal data and background. Substantial data from in 
vitro and in vivo animal experiments (1-9) have shown that he 
induction of sustained atrial fibrillation requires the presence 
of aeetylcholine or vagal tone. Vagal stimulation and acetyl- 
choline have been shown (1) to shorten both the action 
potential duration and the refractory period of canine atrial 
myocardium. Although it is difficult to sustain fibrillation in 
normal canine atria, acetylcholine can reproducibly induce at 
least transient atrial fibrillation when applied directly to the 
atrial surface (2). Atrial fibrillation can also be induced by 
delivering asingle premature stimulus during continuous elec- 
trical stimulation of the vagus nerve (5,25), even with atria of 
normal size and in the tiny atria of puppies (5). Atropine- 
induced vagal blockade diminishes, but does not abolish, these 
effects on atrial refractoriness (2) and terminates acetylcholine- 
induced atrial fibrillation (4). Similarly, induced atrial fibrilla- 
tion cannot be sustained in surgically vagotomized dogs (5). 
This pro-fibrillatory influence of the vagus may be due to 
the inhomogeneous effects of vagal stimulation on different 
parts of the atria (10). There may be differential effects 
between stimulation of the right and the left vagus nerves; 
atrial fibrillation was reported to have been more easily 
induced during stimulation of the right rather than the left 
vagus nerve (5). Vagal modulation thus increases the inhomo- 
geneity or dispersion of atrial refractoriness, resulting in 
nonuniform wavefront propagation, and thereby facilitates 
atrial fibrillation. 
How can atrial fibrillation occur in the absence of vagal 
modulation? In the absence of vagal tone, there must be 
another mechanism responsible for the dispersion in atrial 
refractoriness that is required for the occurrence of atrial 
fibrillation. This dispersion in atrial refractoriness may be due 
to intrinsic myocardial disease or an abnormal neurohormonal 
or electrolyte milieu. Thus, inhomogeneity n atrial refractori- 
ness may be provided by 1) the abnormally large surgical 
atrium of the transplanted heart (more likely to be an impor- 
tant factor for the occurrence of atrial flutter); 2) a diseased 
state of the atrial myocardium due to ischemie injury or 
surgical trauma; 3) abnormal intraatrial conduction due to 
altered anisotropy after atrial surgery; 4) a response to height- 
ened catecholamine stimulation; or 5) increased sensitivity to 
cateeholamine levels. The native (explanted) heart, after pro- 
longed exposure to increased levels of circulating catechol- 
amines, manifests catecholamine r ceptor down-regulation 
(26,27). However, the transplanted ( onor) heart is derived 
from a more normal hormonal milieu and typically demon- 
strates normal or increased catecholamine r ceptor density. 
Several investigators (28,29) have shown that denervation 
increases the sensitivity of beta-adrenergic re eptors to cate- 
cholamine l vels in the transplanted human heart. Thus, the 
transplanted heart may now be exposed to, and indeed dem- 
onstrate enhanced sensitivity to, circulating catecholamine 
levels. The resultant increased ispersion in atrial refractori- 
ness may facilitate the occurrence of atrial fibrillation. This is 
analogous to the proved increase in susceptibility oventricular 
fibrillation during catecholamine stimulation (30,31). 
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Published studies reporting atrial arrhythmias in trans- 
plant recipients. Several published studies have reported that 
atrial arrhythmias do occur in cardiac transplant recipients but 
have generally failed to distinguished between atrial fibrillation 
and flutter. Pooled data from seven studies (14,16-18,20, 
32,33) that did distinguish between the atrial arrhythmia types 
included 347 patients. These pooled data report a 12% inci- 
dence for atrial flutter and an approximate 5% incidence of 
atrial fibrillation. Only two studies (14,20) have reported a
higher incidence of atrial arrhythmias in the posttransplant 
period. Hence, most of the published reports uggest that the 
occurrence of atrial arrhythmias, specifically atrial fibrillation, 
is an uncommon event in this population. 
Present study. Incidence of atrial arrhythmias. Despite 
these earlier reports, our study demonstrates that atrial ar- 
rhythmias in general, and specifically atrial fibrillation, are a 
common occurrence in the denervated transplanted human 
heart. The overall incidence of all atrial arrhythmias (50%) was 
also higher in our study compared with most, but not all, of the 
previous reports, This may be due in part to the fact that we 
noted every instance of atrial arrhythmia, even if relatively 
short-lived. Thus, the mean duration of ectopic atrial tachycar- 
dia in this study was <1 rain, and there were seven patients 
with atrial fibrillation that lasted <6 min. Although atrial 
flutter was more common than atrial fibrillation, this difference 
did not reach statistical significance. 
Atrial fibrillation and death. An unexpected finding of this 
study was the observed association between the occurrence of 
late atrial fibrillation and subsequent mortality. The occur- 
rence of atrial fibrillation was a marker of adverse outcome, 
especially when atrial fibrillation was documented after the 
first 2 weeks after transplantation. The occurrence of atrial 
fibrillation was not simply a preterminal event because it 
predated eath by an average of 77 days. Even brief paroxysms 
of atrial fibrillation were associated with an adverse outcome. 
The explanation for this association is not immediately 
evident. In the absence of vagal modulation, the required 
dispersion of atrial refractoriness for atrial fibrillation to occur 
may be provided by a diseased state of the myocardium or an 
abnormal neurohormonal milieu. Thus, atrial fibrillation in the 
denervated heart may simply be a marker of an underlying 
myocardial disease process and the observed increase in sub- 
sequent mortality a result of progression of that disease 
process. In support of this theory, mean left ventricular 
ejection fraction in the patients with atrial fibrillation tended to 
be less than that of patients without atrial fibrillation, but this 
difference did not reach statistical significance. This hypothesis 
is also consistent with the observations ofHeinz et al. (32), who 
also postulated that there was more extensive lectrical atrial 
abnormality in patients with atrial fibrillation than in those 
with atrial flutter. This same group of investigators (32) also 
noted that in patients with inducible atrial flutter, sinus node 
function (as assessed by measurement of sinus node recovery 
times and sinoatrial conduction times) was entirely normal. 
However, in patients with inducible atrial fibrillation, sinus 
node function was profoundly abnormal. The lack of associa- 
tion between the duration of atrial fibrillation and death is not 
necessarily inconsistent with this hypothesis. Whether atrial 
fibrillation is brief or sustained may simply be reflective of the 
degree of myocardial bnormality orthe degree of endogenous 
catecholamine stimulation. 
The proposed link between recognized atrial fibrillation (as 
a marker of myocardial disease) and death does not directly 
explain the deaths that occurred from noncardiac auses. 
However, it is possible, that the abnormal hormonal milieu in 
these patients with active infection or multisystem failure may 
have facilitated atrial fibrillation. 
Atrial flutter. Mean duration of atrial flutter was signifi- 
cantly greater than that of atrial fibrillation and might have 
been even greater had not four episodes of flutter been 
terminated by cardioversion or overdrive atrial pacing. It is 
possible that atrial flutter was more sustained in the present 
study simply because it may not be dependent on vagal 
modulation. It is not known whether denervation may have a 
"permissive" ffect on the occurrence of atrial flutter. It has 
been suggested (34) that the exaggerated response of the 
denervated heart to endogenous adenosine (35) may play a 
role in the genesis of atrial flutter, particularly in situations 
associated with increased adenosine release, such as hypoxia 
and rejection. The maintenance of atrial flutter requires a 
critical zone of slow conduction (usually located in the antero- 
inferior portion of the interatrial septum, near the tricuspid 
annulus-inferior vena cava isthmus), as evidenced from the 
recent reports (36,37) on radiofrequency ablation for the 
common type of atrial flutter. This zone of slow conduction 
allows a reentrant circuit to be maintained around a zone of 
block. The long anastomotic suture line between the recipient 
and donor atria may provide another line of anatomic block 
that allows sustained reentry to occur in a "corridor" of 
excitable muscle between it and the tricuspid annulus. Thus, a 
minimal change in the electrophysiologic properties of the 
atria (possibly induced by denervation, mechanical handling 
during surgery, creation of an anatomic zone of block from the 
suture line or irritation from sutures) may be sufficient to allow 
atrial flutter to occur. However, for atrial fibrillation to occur, 
a far greater area of the atrium may need to be affected (32). 
Allograft rejection and atrial arrhythmias. Several studies 
have reported an association between cardiac allograft rejec- 
tion and atrial arrhythmias (15-18). However, in our study an 
analysis of the results of endomyocardial biopsy samples that 
were obtained within several days of the atrial arrhythmia, 
revealed that only a minority (16%) of patients with atrial 
arrhythmias had histologic evidence for moderate or severe 
rejection. Further, there was no significant difference in the 
incidence of rejection between the patients with and without 
an atrial arrhythmia. This is in keeping with the findings of 
Little et al. (20) who observed that in patients treated with 
cyclosporine, atrial arrhythmias were just as common in pa- 
tients with rejection as in patients without rejection. Romhilt et 
al. (21) also noted a high prevalence of cardiac arrhythmias 
throughout the transplant period irrespective of acute rejec- 
tion in the donor heart (21). A well recognized limitation of 
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endomyocardial biopsy in detecting histologic rejection is 
sampling error. Rejection may be patchy, and the biopsy 
site may not reflect ongoing rejection in other areas of the 
myocardium. 
Limitations of the study. The acquisition of data in the 
present retrospective analysis was dependent on the degree of 
data entry into the hospital medical record of each patient. In 
the first 2 to 4 weeks after transplantation, patient monitoring 
in the intensive care and stepdown units was continuous, and 
all arrhythmias occurring during the posttransplant period 
were completely documented. However, ECGs were not re- 
corded at all outpatient follow-up visits, and subsequent hos- 
pital admissions were either a result of scheduled annual 
evaluation and coronary angiography or were necessitated by 
intercurrent illness. Thus, late follow-up was more intense for 
the sicker patients, whereas the healthier patients may have 
had asymptomatic late arrhythmias as outpatients that were 
not recorded. Hence it was recognized "late" atrial fibrillation 
that was associated with increased mortality, and the reporting 
of arrhythmias in this study may have underestimated the 
incidence of late asymptomatic arrhythmias in healthy outpa- 
tients. For the same reason, the time from transplantation to
the first occurrence of atrial arrhythmia may have been under- 
estimated because some of the patients without any recognized 
arrhythmia may have had their first (unrecognized) arrhythmia 
episode as an outpatient. 
Another potential limitation is the relatively small sample 
size of this retrospective study. Larger numbers of patients will 
need to be prospectively studied to confirm our preliminary 
observations. 
Conclusions. Despite experimental data to the contrary, 
atrial arrhythmias do occur frequently in the denervated 
transplanted human heart. Further, atrial fibrillation is com- 
monly seen in the transplanted heart in the absence of vagal 
modulation. Atrial fibrillation that is recognized after the first 
2 weeks after transplantation may be a marker of an underlying 
disease process and is associated with an increased risk of 
all-cause mortality. The reasons for this increased risk of death 
remain unclear because <50% of the deaths were directly due 
to cardiac dysfunction. Atrial flutter, on the other hand, is a 
more stable and longer lasting arrhythmia in this population 
and is not associated with an increased risk of subsequent 
mortality. Finally, both atrial flutter and fibrillation can fre- 
quently occur in the absence of histologically significant rejec- 
tion or hemodynamic abnormalities. 
We gratefully acknowledge the assistance of Julia Senges, visiting medical 
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